Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

Finding and checking a clinical trial

In one sentence

Finding a trial means identifying a study and then confirming its protocol, relevant cohort, site availability and formal eligibility with the study team.

The intuition

A trial registry is like a directory of possible appointments. It tells you which study to investigate and how to reach its team. It cannot reserve a place, complete screening or decide whether the study fits someone's care.

The analogy breaks because a study is research, with a protocol that controls treatment and follow-up. A useful shortlist needs both scientific fit and current practical confirmation.

How it works

Start with the disease and treatment setting, then add relevant intervention, biomarker and location terms. Search several sensible synonyms. A target-name search alone can miss studies organized by a drug or platform name, and it can find studies in unrelated cancers.

Use the registry identifier to keep the study distinct from similar titles. ClinicalTrials.gov identifiers begin with NCT followed by digits. The identifier is a record key, not an approval or eligibility certificate.

Read the inclusion and exclusion criteria, study groups, phase and assignment design, outcomes, contacts, locations and record dates. Note what was actually tested or proposed. An investigator-initiated study still needs the same careful reading.

Recruitment status belongs to a defined scope. “Recruiting” describes a study inviting potential participants; it does not establish that the relevant cohort at a nearby site has a slot. “Active, not recruiting” means the study continues but is not currently recruiting or enrolling new participants. “Not yet recruiting” is a future possibility rather than a current opening.

Contact the study team through the registry or verified institutional route. Ask about the exact cohort, site, screening window and remaining eligibility questions. Keep the date and source of each answer. A registry change and a site answer may occur on different dates.

Why it matters in cancer

Eligibility may depend on stage, prior therapy, organ function, safety history, medication use and biomarker definitions. The treating and study teams interpret those rules. Do not change care or stop medicines to satisfy an inferred rule.

Formal screening is a later stage than finding a plausible match. Even an invitation to screen does not guarantee enrollment, and enrollment in a randomized study does not guarantee the experimental treatment.

How the search is documented

This is a record check rather than a measurement with a biological unit. A useful row names the registry identifier, protocol/cohort, site, status, update/verification dates, current team answer and unresolved questions. Mark “unknown” rather than estimating enrollment or assigning an opening based on an old page.

ClinicalTrials.gov listing does not mean the U.S. government has approved the safety and science of the study. Registration, regulatory permission and a well-designed trial are different checks.

Common confusions

  • An estimated enrollment count is not a count of open slots.
  • An overall recruiting status is not confirmation for every site or cohort.
  • A biomarker match is not a full eligibility determination.
  • A closed cohort alone does not establish eligibility for expanded access.

Try it

A fictional registry record says “Recruiting,” but the hospital confirms that its relevant cohort is closed. What belongs in the shortlist?

Answer: Record the study as a scientific lead with local availability unconfirmed or closed, including the dated hospital answer. Another site might be worth asking, but access is not established.

IND versus marketing applications distinguishes investigation from marketing. The trial-access lesson provides a fuller worksheet.

Sources and scope

Source check: October 9, 2026. The case is fictional; no actual recruitment or eligibility is inferred. Expert and learner review pending.

Used in